Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Azithromycin for COVID-19: More Than Just an Antimicrobial?
Nathalie Bleyzac, Sylvain Goutelle, Laurent Bourguignon, et al.
Clinical Drug Investigation (2020) Vol. 40, Iss. 8, pp. 683-686
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

The signal pathways and treatment of cytokine storm in COVID-19
Lan Yang, Xueru Xie, Zikun Tu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 498
Detection of Viral Infections by Innate Immunity
Michael Carty, Coralie Guy, Andrew Bowie
Biochemical Pharmacology (2020) Vol. 183, pp. 114316-114316
Open Access | Times Cited: 295
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients
Apurva Hariharan, Abdul Rahman Hakeem, Subathra Radhakrishnan, et al.
Inflammopharmacology (2020) Vol. 29, Iss. 1, pp. 91-100
Open Access | Times Cited: 266
Antimicrobial Resistance in the Context of the Sustainable Development Goals: A Brief Review
Márió Gajdács, Edit Urbán, Anette Stájer, et al.
European Journal of Investigation in Health Psychology and Education (2021) Vol. 11, Iss. 1, pp. 71-82
Open Access | Times Cited: 124
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
Katharina Habler, Mathias Brügel, Daniel Teupser, et al.
Journal of Pharmaceutical and Biomedical Analysis (2021) Vol. 196, pp. 113935-113935
Open Access | Times Cited: 74
Macrophage Polarization and Plasticity in Systemic Lupus Erythematosus
Mariame Mohamed Ahamada, Yang Jia, Xiaochuan Wu
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 64
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
Xue Li, Ziqi Zhang, Zhenling Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 49
Wastewater surveillance of SARS-CoV-2 and chemical markers in campus dormitories in an evolving COVID − 19 pandemic
Sanjeeb Mohapatra, Sumedha Bhatia, Kavindra Yohan Kuhatheva Senaratna, et al.
Journal of Hazardous Materials (2022) Vol. 446, pp. 130690-130690
Open Access | Times Cited: 40
Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture
Zixuan Yuan, Mahmud Arif Pavel, Hao Wang, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 37
Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence
Kang‐Lin Hsieh, Yinyin Wang, Luyao Chen, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 49
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies
Wissam H. Faour, Ali Choaib, Elio Issa, et al.
Inflammation Research (2021) Vol. 71, Iss. 1, pp. 39-56
Open Access | Times Cited: 49
Adjunctive Nutraceutical Therapies for COVID-19
Lalita Subedi, Stephanie Tchen, Bhakta Prasad Gaire, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1963-1963
Open Access | Times Cited: 45
Antibiotic misuse and compliance with infection control measures during COVID‐19 pandemic in community pharmacies in Egypt
Asmaa A. Elsayed, Samar F. Darwish, Moataz B. Zewail, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 6
Open Access | Times Cited: 40
Self-Medication with Antibiotics during COVID-19 in the Eastern Mediterranean Region Countries: A Review
Feras Jirjees, Munazza Ahmed, Somayeh Sayyar, et al.
Antibiotics (2022) Vol. 11, Iss. 6, pp. 733-733
Open Access | Times Cited: 28
Hospital Antibiotic Consumption before and during the COVID-19 Pandemic in Hungary
Roxána Ruzsa, Ria Benkő, Helga Hambalek, et al.
Antibiotics (2024) Vol. 13, Iss. 1, pp. 102-102
Open Access | Times Cited: 6
Electro-polymerization of modified carbon paste sensor for detecting azithromycin
Salma Mamdouh, M. Shehata, Amany M. Fekry, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico
René Lima-Morales, Pablo Méndez‐Hernández, Yvonne N. Flóres, et al.
International Journal of Infectious Diseases (2021) Vol. 105, pp. 598-605
Open Access | Times Cited: 39
COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?
Feras Jirjees, Ali Saad, Zahraa Al Hano, et al.
Infectious Disease Reports (2021) Vol. 13, Iss. 2, pp. 259-284
Open Access | Times Cited: 36
COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges
Gholam Reza Sivandzadeh, Hassan Askari, Ali Reza Safarpour, et al.
World Journal of Clinical Cases (2021) Vol. 9, Iss. 22, pp. 6178-6200
Open Access | Times Cited: 36
The Impact of the COVID-19 Pandemic on Antibiotic Prescribing Trends in Outpatient Care: A Nationwide, Quasi-Experimental Approach
Tania Silva, Marta Estrela, Eva Gomes, et al.
Antibiotics (2021) Vol. 10, Iss. 9, pp. 1040-1040
Open Access | Times Cited: 32
Environmentally azithromycin pharmaceutical wastewater management and synergetic biocompatible approaches of loaded azithromycin@hematite nanoparticles
Mostafa F. Al-Hakkani, Gamal A. Gouda, Sedky H.A. Hassan, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial
Ahmed Kamal, Ramy Mohamed Ghazy, Dalia Sherief, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 13
The effect of vitamin D, magnesium and zinc supplements on interferon signaling pathways and their relationship to control SARS-CoV-2 infection
Mohsen Nabi‐Afjadi, Hadis Karami, Kaveh Goudarzi, et al.
Clinical and Molecular Allergy (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 27
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
Pawan Kumar Raghav, Zoya Mann, Simran Kaur Ahluwalia, et al.
Journal of Pharmacological Sciences (2023) Vol. 152, Iss. 1, pp. 1-21
Open Access | Times Cited: 11
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
Yiying Xue, Husheng Mei, Yisa Chen, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top